3/29/2024
• Posted by Provider Relations
March 30 is National Doctors Day. On this annual observance, Fidelis Care extends sincere gratitude to the doctors and healthcare professionals across New York State who work tirelessly to support the health and wellness of the members and local communities we serve.
Your service and dedication to achieving enhanced patient outcomes through quality care is a vital pillar of Fidelis Care’s mission of transforming the health of the community.
First commemorated in 1933 by Eudora Brown Almond to honor the contributions of local physicians in Barrow County, Georgia, March 30 was selected because that was the day in 1842 that Dr. Crawford
3/29/2024
• Posted by Provider Relations
Beginning March 2, 2024, current enrollees in Qualified Health Plans (Ambetter from Fidelis Care) who are within 200-250% FPL were notified via letter from NY State of Health about the expansion of Essential Plan (EP) coverage in New York State. Members that now qualify for Essential Plan coverage will automatically be moved from their Qualified Health Plan to Essential Plan 200-250, effective April 1, 2024.
In addition to the Essential Plan Expansion, effective April 1, 2024, NYS will be implementing the EP Pregnancy Choice Provision. Individuals who are currently in EP and who report being pregnant will remain EP eligible, instead
3/29/2024
• Posted by Provider Relations
The following sections of the Fidelis Care authorization grids have been updated effective May 1, 2024.
The following codes have been added on the Medicaid, Medicare, Essential Plan, and Metal-Level Products Authorization Grids and require prior authorization:
C9166 secukinumab
C9167 apadamtase alfa
C9168 mirikizumab-mrkz
J0177 aflibercept hd
J0589 daxibotulinumtoxina-lanm
J1202 miglustat
J1203 cipaglucosidase alfa-atga
J1323 elranatamab-bcmm
J2277 motixafortide
J2782 avacincaptad pegol
J2801 risperidone (Rykindo)
J3055 talquetamab-tgvs
J7165 prothrombin complex concentrate (Balfaxar)
J9073 cyclophosphamide (ingenus)
J9074 cyclophosphamide (sandoz)
J9075 cyclophosphamide, not otherwise specified
J9248 melphalan (hepzato)
J9249 melphalan (apotex)
J9376 pozelimab-bbfg
Q5133 tocilizumab-bavi (tofidence)
Q5134 natalizumab-sztn (tyruko)
The following codes have been added on the Medicare Authorization Grids and require prior authorization:
J0577 buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
J0578
3/25/2024
• Posted by Provider Relations
The METS program is an integrated, whole health approach to support members with significant behavioral health challenges. It includes behavioral health, medical, therapeutic, pharmacy, and supplemental services. METS’ purpose is to focus on the recovery and resiliency of each person. The goal is to help members remain in their community. Members are internally identified using claims history over a 12-month period. If you have a patient identified for the program, a METS Clinical Liaison will reach out to you to discuss the member’s treatment plan and progress.
The METS team partners with both the provider and the member to ensure the member achieves
3/19/2024
• Posted by Provider Relations
Fidelis Care is pleased to inform you that the medical record request letter and details for 2023 HEDIS/QARR have been posted on our Provider Portal, Provider Access Online (PAO). Please review these materials and send the requested documentation to Fidelis Care as soon as possible. Thank you in advance for your cooperation on this important matter. Should you have any questions or concerns, please do not hesitate to contact Fidelis Care’s Provider Call Center at 1-888-FIDELIS (1-888-343-3547).
As part of the New York State Quality Assurance Reporting Requirements (QARR), National Committee for Quality Assurance (NCQA), and HEDIS reporting requirements for the Centers
Newer Articles
Older Articles